Table 1 Overview of studies included
Author | Year | SD (P/R) | Pat. no | Age: median (range) | Machine type | Parameters | b-values (s/mm2) | Tumor diameters (mm) | Malignant | Benign | Main findings |
|---|---|---|---|---|---|---|---|---|---|---|---|
Suo et al. [35] | 2021 | R | 144 | 51.7 ± 11.8 | 3-T Philip | ADC, DDC, D*, f | 0, 10, 30, 50, 100, 150, 200, 500, 800, 1000, 1500, 2000, and 2500 | 39.8 ± 21.2 | NA | NA | Indifferent ADC change at after treatment was a predictor of pCR pre NAC in BC |
Kim et al. [36] | 2018 | R | 46 | 45 (25–67) | 3-T | ADC, D, D*, f | 0, 25, 50, 75, 100, 150, 200, 300, 500 and 800 | 4.15 (2.2–9.3) | NA | NA | D & ADC are suitable for the calculation of response to NAC in BC patients |
Cho et al. [37] | 2017 | R | 31 | 47.40 (28–66) | 1.5 or 3 T | ADC, D, D*, f, VTT% | 0, 30, 60, 90, 120, 250, 400, 600, 800, 1000 | 13.84 (3.43, 44.45) | NA | NA | D value displayed predictive capabilities; measured and heterogeneous D* bid poor prognosis. Baseline ADC&D values were not important interpreters of response |
Che et al. [38] | 2016 | P | 36 | 50.9 (27–75) | 3.0 T | D, D*, f, MD, V | 0, 10, 20, 30, 50, 70, 100, 150, 200, 400, 800, and 1000 | 4.89–1.52 | NA | NA | IVIM factors, particularly the D and f value, displayed likely value in the before-treatment prediction & early response checking to NAC in BC |
Bedair et al. [39] | 2017 | P | 36 | 55 (32–75) | 3.0-T | ADC, DDC, and Dt | 0, 30, 60, 90, 120, 300, 600, 900 | 1.2–12 | NA | NA | DW is sensitive to baseline and early usage vicissitudes in BC by bi-exponential |
He et al. [40] | 2021 | P | 202 | 43.8 ± 9.2 | 3 T Siemens | ADC, D, D*, f, MK, and MD | 0, 30, 50, 80, 120, 160, 200, 500, 1000, 1500, 2000 | NA | 152 | 63 | ADC was improved than that of D* and there was no numerical change among D and MD. There was no significant change in investigative efficiency among ADC alone as related to ADC & MK |
Meng et al. [41] | 2020 | P | 121 | 57 ± 11 | 3 T GE | D, D*, f | 0, 50, 75, 100, 150, 200, 400, 800, 1000 | Malignant: 25.6 ± 11.4; Benign: 22.4 ± 8.9 | 65 | 58 | IVIM-parameter f, D*, and D standards displayed associations with some predictive features for BC |
Song et al. [42] | 2018 | R | 85 | 54 | 3 T Siemens | D, D*, f | 0, 10, 20, 30, 50, 70, 100, 150, 200, 400, 600, 1000 | 18 (8–48) | 85 | 0 | Showing the possibility of IVIM biomarkers to offer info on the biotic and kinematic possessions of BC devoid of a contrast agent |
Zhao et al. [43] | 2018 | R | 141 | 50.2 ± 10.5 | 3 T GE |  | 0, 50, 100, 150, 200, 400, 500, 1000, 1500 | NA | 119 | 22 | The IVIM biomarkers of cancer, tumor superiority and per tumor tissues in many subtypes of BC may perhaps be suitable for difference of BC subtypes and to evaluate the invasive amount of the tumors |
Mao [44] | 2018 | R | 124 | 45.3 ± 8.7 | 3 T Siemens | D, D*, f | 0, 50, 100, 150, 200, 250, 300, 400, 600, 800, 1000, 1200 | NA | 77 | 47 | IVIM canister advantage to increase the specificity & accuracy in difference identification of breast benign & malignant lesions |
Lin et al. [45] | 2017 | P | 93 | 48 | 3Â T Philips | ADC, D, D*, f | 0, 50, 100, 150, 200, 500, 800 | NA | 51 | 47 | IVIM offers measurable quantity of cellularity & vascularity for describing BC. In D displays moral potential for classifying BC |
Iima et al. [46] | 2017 | P | 199 | 58.5 (20–88) | 3 T Siemens | ADC, D, D*, f | 5, 10, 20, 30, 50, 70, 100, 200, 400, 600, 800, 1000, 1500, 2000, 2500 | Benign: 25.7 (10–100); Malignant: 18.2 (10–62) | 152 | 47 | IVIM & non-Gaussian diffusion factors, & their mishmash through integrated diagnostic approaches, may provide BC investigative accuracy like to BI-RADS devoid of the necessity for contrast agents |
Cho et al. [47] | 2016 | R | 62 | 48.44 ± 11.14 | 3 T Siemens | ADC, D, D*, f | 0, 30, 70, 100, 150, 200, 300, 400, 500, 800 | 32.5 ± 27.2 | 50 | 12 | Innovative DWI display relations by molecular predictive aspects & BC. This study illuminate certain of the practical variability in usage response between BC patients |
Wang et al. [48] | 2016 | R | 48 | 46.85 ± 8.63 | 3 T GE | ADC, D, D*, f | 0, 10, 20, 50, 100, 200, 300, 400, 600, 800 | Malignant: 159.9 (82.6–243.2) mm2; Benign: 87.5 | 31 | 23 | D can efficiently accompaniment current predictable DW &DCE in distinguishing malignant since benign BC. IVIM united with DCE is a forceful incomes of assessing BC |
Liu et al. [49] | 2016 | P | 56 | NA | 1.5 T Philips | ADC, D, D*, f, Ktrans, Kep, Ve and Vp | 0, 10, 20, 30, 50, 70, 100, 150, 200, 400, 600, 1000 | Malignant: 28.32 ± 4.25; Benign: 22.27 ± 3.96 | 36 | 23 | IVIM is suitable in the difference of BC. Important associations were found among perfusion parameters as of DCE &IVIM. IVIM may be a suitable adjunctive instrument to standard MRI in detecting BC |
Bokacheva et al. [50] | 2014 | R | 35 | 57 | 3 T GE | ADC, D, D*, f | 0, 30, 60, 90, 120, 400, 600, 800, 1000 | Benign: 20 (8–48); Malignant: 38 (9–80) | 26 | 14 | The IVIM biomark offer exact documentation of malignant lesions |